X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.prnewswire.com/news-releases/csl-vifor-and-travere-therapeutics-announce-european-commission-approves-filspari-sparsentan-for-the-treatment-of-iga-nephropathy-302125154.html
https://www.globenewswire.com/news-release/2024/04/24/2868483/0/en/Travere-Therapeutics-and-CSL-Vifor-Announce-European-Commission-Approves-FILSPARI-sparsentan-for-the-treatment-of-IgA-Nephropathy.html
https://www.prnewswire.com/news-releases/renalys-pharma-submits-an-ind-application-for-a-phase-iii-clinical-trial-of-sparsentan-for-iga-nephropathy-in-japan-302109189.html
https://www.globenewswire.com/news-release/2024/04/03/2857380/0/en/Travere-Therapeutics-to-Present-Abstracts-on-FILSPARI-sparsentan-in-IgA-Nephropathy-at-World-Congress-of-Nephrology-and-the-American-Nephrology-Nurses-Association.html
https://www.globenewswire.com//news-release/2024/03/11/2843642/0/en/Travere-Therapeutics-Submits-Supplemental-New-Drug-Application-to-the-U-S-Food-and-Drug-Administration-Seeking-Full-Approval-of-FILSPARI-sparsentan-for-the-Treatment-of-IgA-Nephrop.html
https://www.reuters.com/business/healthcare-pharmaceuticals/travere-drug-rare-kidney-condition-recommended-eu-approval-2024-02-23/
https://www.fiercepharma.com/pharma/traveres-filspari-misses-kidney-disease-trial-removal-market-looks-unlikely-analysts
https://www.globenewswire.com//news-release/2023/09/21/2747170/0/en/Travere-Therapeutics-Announces-Confirmatory-Data-from-the-Phase-3-PROTECT-Study-of-FILSPARI-Demonstrating-Long-Term-Kidney-Function-Preservation-in-IgA-Nephropathy-Narrowly-Missing.html
https://www.fiercebiotech.com/biotech/travere-fails-beat-label-blood-pressure-drug-phase-3-plans-talks-fda-anyway
https://www.prnewswire.com/news-releases/topline-results-from-two-year-primary-efficacy-endpoint-in-pivotal-phase-3-duplex-study-of-sparsentan-in-focal-segmental-glomerulosclerosis-301813250.html
https://www.globenewswire.com/news-release/2023/04/01/2639124/0/en/Travere-Therapeutics-Announces-Interim-Analysis-from-the-Phase-3-PROTECT-Study-of-FILSPARI-Sparsentan-in-IgA-Nephropathy-Published-in-The-Lancet-and-Presented-at-World-Congress-of-.html
https://www.fiercepharma.com/marketing/travere-fda-approval-bristol-myers-castoff-unique-drug-rare-kidney-disease
https://www.biospace.com/article/releases/travere-therapeutics-announces-fda-acceptance-and-priority-review-of-new-drug-application-for-sparsentan-for-the-treatment-of-iga-nephropathy/
https://www.globenewswire.com/news-release/2022/03/21/2406525/0/en/Travere-Therapeutics-Submits-New-Drug-Application-for-Sparsentan-for-the-Treatment-of-IgA-Nephropathy.html
https://www.fiercebiotech.com/biotech/vifor-doles-out-55m-upfront-to-license-travere-s-late-stage-kidney-asset-slated-for
https://seekingalpha.com/pr/18461612-travere-therapeutics-announces-successful-outcome-from-type-meeting-u-s-fda-for-sparsentan-in
https://www.empr.com/home/news/drugs-in-the-pipeline/fda-orphan-drug-designation-sparsentan-immunoglobulin-nephropathy/#:~:text=Sparsentan%20has%20a%20dual%20mechanism,immunoglobulin%20A%20(IgA)%20nephropathy.
https://www.fiercebiotech.com/biotech/retrophin-sheds-shkreli-connection-new-name-travere-therapeutics
https://endpts.com/retrophin-no-more-shkrelis-legacy-disappears-as-former-company-becomes-travere-therapeutics/
https://www.biospace.com/article/releases/retrophin-completes-acquisition-of-orphan-technologiesaddition-of-ot-58-strengthens-pipeline-of-potential-first-in-class-therapies-targeting-rare-diseases/?s=79
http://ir.retrophin.com/news-releases/news-release-details/retrophin-announces-agreement-acquire-orphan-technologies
http://ir.retrophin.com/news-releases/news-release-details/retrophin-announces-agreement-acquire-orphan-technologies#:~:text=(NASDAQ%3A%20RTRX)%20today%20announced,of%20classical%20homocystinuria%20(HCU).
https://www.biospace.com/article/retrophin-buys-orphan-technologies-in-517-million-deal/?s=79
https://www.biospace.com/article/releases/retrophin-announces-agreement-to-acquire-orphan-technologies/?s=79
https://www.globenewswire.com/news-release/2020/10/09/2106466/0/en/Retrophin-Announces-Presentation-of-Abstracts-at-ASN-Kidney-Week-2020-Reimagined.html
Market Place
Share 
